Castle Biosciences, Inc. - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
CSTL Nasdaq 8081 castlebiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Castle Biosciences, Inc.

Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - Apr 10th, 2026 5:00 am
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) - Apr 4th, 2026 5:07 pm
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Mar 27th, 2026 7:05 am
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - Mar 23rd, 2026 4:36 pm
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets - Mar 20th, 2026 10:14 pm
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - Mar 17th, 2026 8:40 am
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - Mar 17th, 2026 8:35 am
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - Mar 13th, 2026 10:05 am
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB - Mar 13th, 2026 9:02 am
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - Mar 12th, 2026 9:30 am
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - Mar 9th, 2026 5:00 am
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Mar 6th, 2026 11:07 am
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB - Mar 4th, 2026 2:30 pm
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Mar 3rd, 2026 2:30 pm
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria - Mar 2nd, 2026 7:10 am
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - Feb 27th, 2026 10:35 am
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Feb 27th, 2026 7:34 am
Castle Biosciences, Inc. Q4 2025 Earnings Call Summary - Feb 27th, 2026 6:30 am
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Feb 26th, 2026 10:06 pm
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Feb 26th, 2026 4:00 pm